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Abstract
There is a complex interplay between the cells of the immune system and bone. These inter-
actions are not only mediated by the release of cytokines and chemokines but also by direct 
cell–cell contact. Studies of intracellular signaling mechanisms in osteoclasts have revealed that 
numerous immunomodulatory molecules are involved in the regulation of bone metabolism. 
Recently, it was proposed that immunoreceptors found in the immune cells are also an essen-
tial signal for osteoclasts activation, along with receptor activator of NF-κB (RANK) ligand 
(RANKL). Collectively, these and similar observations regarding cross-regulation between the 
immune and skeletal systems constitute the field of osteoimmunology. Here we briefly high-
light core areas of interest and selected recent advances in this field.
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Introduction
The term osteoimmunology was used for the first time in 2000 (Arron et al., 2000) 
to describe the interaction of cells of the immune and skeletal systems. In fact, one 
year before, receptor activator of NF-κB (RANK) ligand (RANKL) was found in T 
lymphocytes and described as a regulator of dendritic cell and osteoclast function, 
having an important role in promoting osteoclastogenesis (Rho et al, 2004; Takay-
anagi, 2012). Immune and skeletal systems have several regulatory factors in com-
mon, such as cytokines, transcription factors and receptors. Consequently, these two 
systems interact with each other in both physiological and pathological conditions. 
In particular, pathological activation of one system affects the other, such as in the 
case of rheumatoid arthritis where abnormal activation of the immune system affects 
bone remodelling leading to pathological bone erosions. During chronic inflamma-
tion, the balance between bone formation and resorption is skewed towards osteo-
clast-mediated resorption. Moreover, in inflamed joints osteoclasts are located at the 
interface between the inflamed synovium and bone and, as in physiological condi-
tions, the RANKL/RANK/OPG system is the major player in bone resorption (Her-
man et al., 2008).
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RANK/RANKL/OPG system
Rank receptor
RANK belongs to the TNFR superfamily. It is synthesized as a type I transmem-
brane protein of 616 amino acids and assembles into a functional trimer. RANK is 
expressed by several tissues, such as skeletal muscle, thymus, liver, colon, mammary 
glands, prostate, pancreas, and by several cell types, such as cells of the monocyte/
macrophage lineage including precursors and mature osteoclasts, B and T lympho-
cytes, dendritic cells, fibroblasts, and articular chondrocytes. The activation of RANK 
stimulates the differentiation of osteoclastic precursors into mature osteoclasts as well 
as the activation of mature osteoclasts.
Rankl cytokine
RANKL is also called TNF-related activation-induced cytokine, TRANCE; osteoclast 
differentiation factor, ODF; and osteoprotegerin ligand, OPGL. It is a type II transmem-
brane protein belonging to the TNF superfamily, whose gene was cloned fifteen years 
ago by four different groups contemporaneously (Anderson et al., 1997; Wong et al., 
1997; Lacey et al., 1998; Yasuda et al., 1998). It exists predominantly in a membrane-
bound form, with a short cytoplasmic N-terminal domain and a single transmem-
brane region, but a soluble form can be generated through alternative splicing (Ikeda 
et al., 2001) or through the cleavage by matrix metalloproteinases and ADAMs (disin-
tegrin and metalloproteinase domain-containing proteins) (Lum et al., 1999; Hikita et 
al., 2007; Hikita et al., 2009). RANKL aggregates into homotrimers through conserved 
and specific residues in the extracellular domain, and trimerization is essential for the 
activation of its cognate receptor RANK (Lam et al., 2001). Recently, the crystal struc-
ture of human RANKL in complex with its decoy receptor osteoprotegerin (OPG) has 
been determined, showing that in this case a different mode of interaction takes place, 
directly blocking the accessibility of residues of RANKL important for RANK recog-
nition (Luam et al., 2012; Nelson et al., 2012). RANKL is broadly expressed, including 
both skeletal and extra-skeletal sites and many diverse cell types: mammary epitheli-
al cells, keratinocytes, vascular endothelial cells, and synovial fibroblasts (Lacey et al., 
1998; Narducci et al., 2009; Nicolin et al., 2008). In the bone, it is produced mainly by 
cells of mesenchymal origin, osteoblasts, hypertrophic chondrocytes, and bone marrow 
(BM) stromal cells; recently, osteocytes have been identified as another source of this 
cytokine (Atkins et al., 2000). In particular, concerning the immune system RANKL is 
produced by several cell types including monocytes, neutrophils, dendritic cells, B and 
T lymphocytes. In this way, immune cells have the ability to induce osteoclast differen-
tiation and, consequently, bone resorption. Also, these cells are known for producing a 
variety of pro-inflammatory cytokines that contribute to bone damage by potentiating 
the effects of the RANK–RANKL signalling (Herman et al., 2008). 
OPG cytokine
First in 1997 two independent groups identified a potent inhibitor of osteoclas-
togenesis named osteoprotegerin (OPG) (Lacey et al., 1998; Simonet et al., 1997) by 
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Amgen investigators in the USA and osteoclastogenesis inhibitory factor (OCIF) (Tsu-
da et al., 1997; Matsuzaki et al., 1998) by investigators in Japan. OPG belongs to the 
TNF receptor (TNFR) superfamily, but differs from the common membrane TNFR in 
that it is soluble. OPG is produced as a pro-protein of 401 amino acids and undergoes 
an intracellular cleavage resulting in a final 380 amino acids mature protein (Kho-
sla et al., 2001). OPG functions as an endogenous antagonist receptor that prevents 
the biological effects of RANKL, both membranous and soluble, and thus acts as an 
inhibitor of bone remodelling/resorption. OPG is highly expressed in the adult lung, 
heart, kidney, liver, thymus, lymph nodes and bone marrow, osteoblasts, vascular 
smooth muscle cells, B lymphocytes, and articular chondrocytes (Simonet et al., 1997). 
OPG can directly inhibit osteoclast activity, independently of RANKL, through inter-
actions with receptors present on osteoclasts. The biological effects of OPG on bone 
cells include inhibition of the terminal stages of osteoclast differentiation, suppression 
of mature osteoclast activation and induction of apoptosis of these cells.
Role of the RANK/RANKL/OPG pathway in bone resorption
The RANK/RANKL/OPG signaling pathway is essential for oesteoclastogen-
esis, as previously discussed: the binding of RANKL (produced by osteoblasts) to 
RANK, located on the surface of osteoclast precursors, recruits the cytoplasmic 
adapter protein tumour necrosis factor receptor-αssociated factor 6 (TRAF6), leading 
to NF-κB activation and translocation to the nucleus; in the nucleus, the translocated 
NF-κB increases the expression of c-Fos; the interaction of c-Fos with nuclear factor 
of activated T-cells, cytoplasmic 1 (NFATc1), leads to increased expression of various 
osteoclastogenic genes; consequently, osteoclast formation is increased resulting in 
increased bone resorption (Fig.1). 
RANK/RANKL/OPG key triad of osteoimmunology
The generation of thymus microenvironment which will allow self-tolerance and 
avoidance of auto-immunity to be established by the deletion of self-reactive T cells. 
Moreover, RANKL has been shown to play a role in a pathological model of inflam-
matory bowel disease by stimulating dendritic cells, suggesting that RANKL is dis-
tinctly involved in the activation of dendritic cells under certain autoimmune con-
ditions.  It has been shown that some members of the tumor necrosis factor (TNF) 
superfamily play major roles in regulating bone metabolism. The molecular triad 
composed of OPG/RANK/RANKL, members of this superfamily, has been described 
as a key cytokine system for controlling the differentiation and function of osteo-
clast biology. Moreover, independent of the bone system, studies have also revealed 
new and important functions of this triad in other pathologies and tissues including 
the immune system. For example, RANKL produced by B cells also contributes to 
bone resorption during periodontal infection and to the increase in osteoclasts and 
in trabecular bone loss upon estrogen withdrawal. Based on these interconnections, 
the RANKL/RANK axis has been defined an essential regulator of both immune 
responses and bone physiology. Several reports have highlighted the cross-talk 
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between immune and bone cells through this molecule, and the importance of the 
contribution of immune cells becomes particularly evident in pathological conditions. 
The RANKL cytokine has been a pioneering discovery in the field of osteoimmunol-
ogy; the elucidation of its signalling pathway has shown the first of the many, and 
continuously increasing, interconnections between bone and immune systems.
Advances in the understanding of bone biology and the role of the RANK/
RANKL/OPG pathway have opened new treatment avenues for osteoporosis.
Conflict of interests
All authors state that they have no conflict of interests to declare. The authors 







IKK c-Src ?? ??





Figure 1 – Interplay between RANK and RANKL during bone resorption.
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